Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback